The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience
British Journal of Haematology(2012)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要